This content is from: Patents
AG weighs in on SPCs in Teva v Gilead opinion
Advocate General Wathelet has rejected the UK court’s suggestion that “core inventive advance” is a relevant consideration in determining whether a basic patent protects an active ingredient within the meaning of Article 3(a)
Get Free Access to read more …
To read the full article, activate your free trial.
Get Free Access- Unlimited articles for one week
- No commitments; no payment details required
- Featuring IP strategy, copyright, patents, trademark and more!
Are you a Managing IP subscriber? Simply login here.